Seminars in Oncology
Volume 37, Issue 3 , Pages 190-201 , June 2010

Cancer Prevention I: Introduction

  • Barbara K. Dunn
    • ,
  • Peter Greenwald

      Affiliations

    • Corresponding Author InformationAddress correspondence to Peter Greenwald, MD, DrPH, Director, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6030 Executive Blvd, Room 6020, MSC 7309, Bethesda, MD 20892-7309

References 

  1.  Greenwald P,  Cullen JW,  Weed DCancer Prevention and Control. Semin Oncol. 1990;17(4):
  2. Greenwald P, Cullen JW, Weed D. Introduction: cancer prevention and control. Semin Oncol. 1990;17:383–390
  3. Greenwald P, Dunn BK. Landmarks in the history of cancer epidemiology. Cancer Res. 2009;69:2151–2162
  4. Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009;69:5269–5284
  5. Blackburn EH. Highlighting the science of cancer prevention. Cancer Prev Res (Phila Pa). 2010;3:393
  6. COMMIT Research Group. Community Intervention Trial for Smoking Cessation (COMMIT): summary of design and intervention. J Natl Cancer Inst. 1991;83:1620–1628
  7. Stillman FA, Cronin KA, Evans WD, Ulasevich A. Can media advocacy influence newspaper coverage of tobacco: measuring the effectiveness of the American stop smoking intervention study's (ASSIST) media advocacy strategies. Tobacco Control. 2001;10:137–144
  8. Manley M, Lynn W, Payne Epps R, Grande D, Glynn T, Shopland D. The American Stop Smoking Intervention Study for cancer prevention: an overview. Tobacco Control. 1997;6(Suppl 2):S5–S11
  9. Hall NG, Hershey JC, Kessler LG, Stotts RC. A model for making project funding decisions at the National Cancer Institute. Oper Res. 1992;40:1040–1052
  10. Stillman FA, Hartman AM, Graubard BI, Gilpin EA, Murray DM, Gibson JT. Evaluation of the American Stop Smoking Intervention Study (ASSIST): a report of outcomes. J Natl Cancer Inst. 2003;95:1681–1691
  11. Lubetkin EI, Lu WH, Krebs P, Yeung H, Ostroff JS, et al. Exploring primary care providers' interest in using patient navigators to assist in the delivery of tobacco cessation treatment to low income, ethnic/racial minority patients. J Commun Health. 2010 Mar 25;Epub ahead of print
  12. American Society of Clinical Oncology. Tobacco control: reducing cancer incidence and saving lives. J Clin Oncol. 1996;14:1961–1963
  13. Curfman GD, Morrissey S, Drazen JM. The FDA and tobacco regulation. N Engl J Med. 2008;359:1056–1057
  14. Deyton L, Sharfstein J, Hamburg M. Tobacco product regulation—a public health approach. N Engl J Med. 2010;362:1753–1756
  15. The Surgeon General Report on Nutrition and Health. DHHS (PHS) publication 88-50210 Washington, DC: US Department of Health and Human Services; 1988;
  16. Neill K, Allensworth DD. A model to increase consumption of fruit and vegetables by implementing the “5-A-Day” initiative. J Sch Health. 1994;64:150–155
  17. Heimendinger J, Chapelsky D. The national 5 A Day for Better Health Program. Adv Exp Med Biol. 1996;401:199–206
  18. 5 A Day For Better Health Program. http://www.5aday.gov/Last accessed June 8, 2010
  19. Potter J, Finnegan J, Guinard JX. 5 A Day for Better Health Program evaluation report (NIH publication no. 01-4904). Bethesda, MD: National Institutes of Health, National Cancer Institute; 2000;
  20. Stables GJ, Subar AF, Patterson BH, et al. Changes in vegetable and fruit consumption and awareness among US adults: results of the 1991 and 1997 5 A Day for Better Health Program surveys. J Am Diet Assoc. 2002;102:809–817
  21. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85:1483–1492
  22. Li JY, Taylor PR, Li B, Dawsey S, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst. 1993;85:1492–1498
  23. Guo W, Blot WJ, Li JY, et al. A nested case-control study of oesophageal and stomach cancers in the Linxian nutrition intervention trial. Int J Epidemiol. 1994;23:444–450
  24. Qiao YL, Dawsey SM, Kamangar F, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst. 2009;101:507–518
  25. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–1155
  26. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–1035
  27. Clark LC, Combs GF, Turnbull BW, et al. Nutritional Prevention of Cancer Study Group Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin (A randomized controlled trial). JAMA. 1996;276:1957–1963
  28. Dunn BK, Ryan A, Ford LG. Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. In:  Senn H-J,  Kapp U,  Otto F editor. Cancer prevention II. Berlin: Springer-Verlag; 2009;p. 183–193
  29. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51
  30. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109
  31. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:629–642
  32. Beresford SA, Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:643–654
  33. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684–696
  34. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007;
  35. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  36. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–1662
  37. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–2741
  38. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila Pa). 2010;3:696–706
  39. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  40. Kaluzny AD, Warnecke RB. Managing a health care alliance (Improving community cancer care). San Francisco: Josey-Bass; 1996;
  41. Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa). 2008;1:32–38
  42. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005;5:142–149
  43. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol. 2007;60:1205–1219
  44. Gohagan JK, Prorok PC, Hayes RB, Kramer BS Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(Suppl):251S–272S
  45. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(Suppl):349S–355S
  46. Gershon-Cohen J, Colcher AE. An evaluation of the roentgen diagnosis of early carcinoma of the breast. JAMA. 1937;108:867–871
  47. Strax P, Venet L, Shapiro S, Gross S, Venet W. Breast cancer found on repetitive examination in mass screening. Arch Environ Health. 1970;20:758–763
  48. Ernster VL. Mammography screening for women aged 40 through 49—a guidelines saga and a clarion call for informed decision making. Am J Public Health. 1997;87:1103–1106
  49. National Institutes of Health Consensus Development Conference Statement (breast cancer screening for women ages 40-49). http://consensus.nih.gov/1997/1997BreastCancerScreening103html.htm1997;Last accessed May 20, 2010
  50. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–726
  51. Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ, et al. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg. 2005;92:429–434
  52. Daly MB. Tamoxifen in ductal carcinoma in situ. Semin Oncol. 2006;33:647–649
  53. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000
  54. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14:370–378
  55. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627–637
  56. Allred DC. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone. J Natl Cancer Inst. 2010;102:585–587
  57. International Early Lung Cancer Action Program InvestigatorsHenschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763–1771
  58. NLST, National Lung Screening Trial. http://clinicaltrials.gov/ct2/show/NCT00047385Last accessed May 20, 2010
  59. NLST, National Lung Screening Trial (NLST). http://www.cancer.gov/nlstLast accessed May 20, 2010
  60. Hocking WG, Hu P, Oken MM, et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. J Natl Cancer Inst. 2010;102:722–731
  61. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Berry LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86:97–100
  62. Seymour L, Ivy SP, Sargent D, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010;16:1764–1769
  63. Gail MH, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–1886

PII: S0093-7754(10)00090-4

doi: 10.1053/j.seminoncol.2010.06.011

Seminars in Oncology
Volume 37, Issue 3 , Pages 190-201 , June 2010

Article Tools